Our approach

Formulations with exceptional stability, offered in multiple presentations

Formulation options

Jurata’s formulations preserve the activity of biologic materials by stabilizing their three-dimensional structure. Initially applied to gene therapies and vaccines, our technology has now shown promise across a broad range of cargoes. The ability to maintain efficacy has been demonstrated at ambient and elevated temperatures.

The same novel material forms the basis of all three Jurata formulation types:

Film

Films can be used directly for sublingual, buccal, or oral administration, or can be reconstituted for use as a liquid. A key benefit of the film presentation is its light weight and small footprint, enabling cost-savings in shipping and storage.

Liquid

The liquid presentation can be filled in vials or any standard administration device (e.g, autoinjector pen). Intravenous, intramuscular, and subcutaneous injection administration routes are all enabled, as is oral administration.

DIVA

Our Dry In Vial Ambient (DIVA) presentation enables a dried lyophilization-free format for ambient shipping and storage, with reconstitution to liquid format at the point of use.

Benefits of Our Formulations

A transformation in the manufacturing, distribution, and administration of vaccines and biologics

  • Jurata enables more efficient manufacturing of complex biologics by eliminating the need for lyophilization in processes such as the production of certain peptides, regardless of formulation or route of administration.

  • Medicines can be shipped to pharmacies, patients’ homes, or to remote global locations without loss of efficacy or compromised quality; once delivered, patients and providers do not need to worry about maintaining temperature control.

    • Jurata’s technology demonstrates exceptional long-term stability for vaccines and other therapeutic cargoes, even at ambient or elevated temperatures.

    • Efficacy is maintained after three days at 40°C or three years at 25°C.

  • Jurata’s stability benefits are available regardless of presentation, allowing choice of administration route to optimize each medicine.

    • Oral, intranasal, sublingual, and buccal administration open up possibilities for needle-free solutions that don’t require specialized healthcare personnel or office visits.

    • Liquid or DIVA formulations can be used for all types of injectable administration, enabling improvements in manufacturing, shipping, and storage without changes to established medical routines.

Proven across multiple modalities

Jurata formulations stabilize vaccines, biologics, gene therapies, and other APIs.

  • Live Attenuated Vaccines

  • Inactivated Vaccines

  • Recombinant Vaccines

  • Subunit Vaccines

  • VLPs

  • Toxoid Vaccines

  • Viral and Bacterial Platforms

  • mRNA LNPs

  • Antibodies/Antibody-Enzyme Conjugate

  • Plasmid DNA

  • Peptides

  • Proteins